Repositioning Candidate Details
| Candidate ID: | R1454 |
| Source ID: | DB12565 |
| Source Type: | investigational |
| Compound Type: | small molecule |
| Compound Name: | Abexinostat |
| Synonyms: | Abexinostat |
| Molecular Formula: | C21H23N3O5 |
| SMILES: | CN(C)CC1=C(OC2=CC=CC=C12)C(=O)NCCOC1=CC=C(C=C1)C(=O)NO |
| Structure: |
|
| DrugBank Description: | Abexinostat has been used in trials studying the treatment of Sarcoma, Lymphoma, Leukemia, Lymphocytic, and Hodgkin Disease, among others. It is a novel, broad-spectrum hydroxamic acid-based inhibitor of histone deacetylase (HDAC) with potential antineoplastic activity. |
| CAS Number: | 783355-60-2 |
| Molecular Weight: | 397.431 |
| DrugBank Indication: | -- |
| DrugBank Pharmacology: | -- |
| DrugBank MoA: | Abexinostat is a novel histone deacetylase (HDAC) inhibitor. HDAC inhibitors target HDAC enzymes and inhibit the proliferation of cancer cells and induce cancer cell death, or apoptosis. Histone deacetylation is carried out by a family of related HDAC enzymes. Inhibition of these enzymes causes changes to chromatin structure and to gene expression patterns, which results in the inhibition of proliferation of cancer cells, and induction of apoptosis . |
| Targets: | Histone deacetylase 1 |
| Inclusion Criteria: | Therapeutic strategy associated |
